RETA / IGF-1 LR3Explore study findings
What a retatrutide outcomes trial can establish about kidney events
3 numbered sourcesSource years 1995–2026
Peptides are short amino-acid chains connected by peptide bonds. Some are made to activate particular hormone receptors. Retatrutide is an investigational peptide that acts on GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This catalog entry names the two together. An ongoing retatrutide trial illustrates which kidney and heart outcomes are being studied for one component. [1, 2, 3]
The TRIUMPH-Outcomes registry describes a randomized phase 3 comparison of retatrutide and placebo in people with excess body weight and cardiovascular disease, chronic kidney disease or both. Its cardiovascular and kidney outcome measures are designed to track events over time. This differs from an early study that records a short-term change in a blood marker or measures the size of an organ. A trial with clinical events can examine whether those events occur at different rates in the assigned groups. [1]
An older experiment with IGF-1 LR3 in guinea pigs reported changes in organ growth and circulating growth-related factors. Organ size and kidney function are different outcomes. Changes in the first do not indicate a lower rate of the events planned for measurement in TRIUMPH-Outcomes. The animal study also used IGF-1 LR3 separately from retatrutide. [3]
The registry lists no results by November 8, 2026, and it does not list an arm receiving IGF-1 LR3. I found no published clinical outcome comparison for the named pair. Data from the ongoing trial can answer the question about the assigned retatrutide intervention once results are available. Estimating the outcome of adding a growth-factor analog would require a comparison that includes it. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Eli Lilly and Company. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. ClinicalTrials.gov (publication 2024-04-25, record updated 2026-10-08). (opens in a new tab)
clinicaltrials.gov↩ Back to text
